Overactive Bladder Clinical Trials

• A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
  ClinicalTrials.gov Identifier: NCT00368706 - Active, not recruiting
  Overactive Bladder
  
• A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00290563 - Active, not recruiting
  Urinary Incontinence; Overactive Bladder
  
• SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
  ClinicalTrials.gov Identifier: NCT00507169 - Active, not recruiting
  Overactive Bladder (OAB)
  
• A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
  ClinicalTrials.gov Identifier: NCT00337558 - Active, not recruiting
  Overactive Bladder; Urinary Incontinence; Urge Incontinence
  
• Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms
  ClinicalTrials.gov Identifier: NCT00343486 - Recruiting
  Overactive Bladder
  
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00311376 - Recruiting
  Overactive Bladder
  
• Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
  ClinicalTrials.gov Identifier: NCT00431041 - Recruiting
  Overactive Bladder
  
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00439140 - Recruiting
  Overactive Bladder
  
• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00444925 - Recruiting
  Overactive Bladder
  
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00461292 - Recruiting
  Overactive Bladder
  
• Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
  ClinicalTrials.gov Identifier: NCT00465894 - Recruiting
  Overactive Bladder; Postmenopausal
  
• Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder.
  ClinicalTrials.gov Identifier: NCT00479505 - Recruiting
  Urinary Bladder, Overactive
  
• The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00553657 - Recruiting
  Overactive Bladder
  
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00575016 - Recruiting
  Overactive Bladder
  
• A Phase 1 Multicenter Study of Three Escalating Doses of hMaxi-K Gene Transfer in Female Participants With Overactive Bladder Syndrome and Detrusor Overactivity
  ClinicalTrials.gov Identifier: NCT00495053 - Recruiting
  Overactive Bladder
  
• Long-Term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00512785 - Recruiting
  Overactive Bladder
  
• Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder (OAB). A Multicenter Phase II, Randomized, Double-Blind, Placebo Controlled 6 Month Study .
  ClinicalTrials.gov Identifier: NCT00231491 - Recruiting
  Overactive Bladder (OAB)
  
• A Research Study for Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00168454 - Recruiting
  Overactive Bladder; Urinary Incontinence
  
• A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00321477 - Recruiting
  Overactive Bladder
  
• Overactive Bladder Innovative Therapy Trial (OrBIT)
  ClinicalTrials.gov Identifier: NCT00448175 - Recruiting
  Overactive Bladder
  
• Local Anesthetic Treatments for Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00427648 - Recruiting
  Overactive Bladder
  
• SSR240600C Treatment in Women With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00564226 - Recruiting
  Overactive Bladder
  
• A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.
  ClinicalTrials.gov Identifier: NCT00561951 - Recruiting
  Overactive Bladder
  
• Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00578097 - Not yet recruiting
  Overactive Bladder
  
• A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects with Overactive Bladder Syndrome
  ClinicalTrials.gov Identifier: NCT00138723 - Completed
  Overactive Bladder
  
• Fesoterodine "Add-on" Male Overactive Bladder Study
  ClinicalTrials.gov Identifier: NCT00546637 - Recruiting
  Overactive Bladder Syndrome
  
• A Study of YM178 in Patients With Symptomatic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00527033 - Not yet recruiting
  Urinary Bladder, Overactive
  
• Programmable Timer in the Bladder Rehabilitation Treatment of OAB
  ClinicalTrials.gov Identifier: NCT00238680 - Active, not recruiting
  Overactive Bladder; Urinary Incontinence
  
• Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00171184 - Completed
  Overactive Bladder
  
• A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
  ClinicalTrials.gov Identifier: NCT00425100 - Completed
  Overactive Bladder
  
• A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
  ClinicalTrials.gov Identifier: NCT00454896 - Completed
  Urinary Bladder, Overactive
  
• Open-Label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
  ClinicalTrials.gov Identifier: NCT00463541 - Completed
  Urinary Bladder, Overactive
  
• A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00170755 - Completed
  Overactive Bladder Syndrome
  
• Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
  ClinicalTrials.gov Identifier: NCT00212732 - Completed
  Overactive Bladder
  
• Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
  ClinicalTrials.gov Identifier: NCT00212706 - Completed
  Overactive Bladder
  
• Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00224146 - Completed
  Overactive Bladder; Urinary Incontinence; Quality of Life
  
• A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
  ClinicalTrials.gov Identifier: NCT00171145 - Completed
  Overactive Bladder Syndrome
  
• Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00366002 - Completed
  Overactive Bladder (OAB)
  
• MILADY: A Randomized, Placebo-Controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.
  ClinicalTrials.gov Identifier: NCT00174798 - Completed
  Overactive Bladder
  
• Efficacy & Safety Study of VESIcare® in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00454740 - Completed
  Urinary Bladder, Overactive
  
• Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
  ClinicalTrials.gov Identifier: NCT00481728 - Recruiting
  Overactive Bladder
  
• A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00189800 - Completed
  Overactive Bladder
  
• A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
  ClinicalTrials.gov Identifier: NCT00337090 - Completed
  Overactive Bladder
  
• A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00501267 - Completed
  Overactive Bladder
  
• Evaluate Efficacy and Safety of Tolterodine Extended Release Capsule Compared with Tolterodine Immediate Release Tablet in Patients with Symptoms of Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00139724 - Completed
  Overactive bladder
  
• A Study To Assess If 10 mg Vardenafil (BAY 38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
  ClinicalTrials.gov Identifier: NCT00478881 - Recruiting
  Overactive Bladder; Detrusor Overactivity
  
• Detrol LA In Men With Overactive Bladder.
  ClinicalTrials.gov Identifier: NCT00282932 - Completed
  Overactive Bladder (OAB)
  
• A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
  ClinicalTrials.gov Identifier: NCT00350636 - Completed
  Overactive Bladder
  
• Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
  ClinicalTrials.gov Identifier: NCT00332319 - Terminated
  Overactive Bladder
  
• A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
  ClinicalTrials.gov Identifier: NCT00220363 - Completed
  Overactive Bladder Syndrome
  
• Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity
  ClinicalTrials.gov Identifier: NCT00437528 - Recruiting
  Overactive Bladder; Urge Urinary Incontinence; Enuresis; Self Clean Intermittent Catheterization
  
• A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00231790 - Active, not recruiting
  Urinary Incontinence
  
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
  ClinicalTrials.gov Identifier: NCT00220376 - Completed
  Overactive Bladder Syndrome
  
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
  ClinicalTrials.gov Identifier: NCT00220402 - Completed
  Overactive Bladder Syndrome
  
• Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
  ClinicalTrials.gov Identifier: NCT00220389 - Completed
  Overactive Bladder
  
• ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
  ClinicalTrials.gov Identifier: NCT00439192 - Terminated
  Overactive Bladder; Urinary Incontinence
  
• A Study Evaluating the Safety, Effectiveness, and Pharmacokinetics of Transdermal Oxybutynin in Treating Overactive Bladder Associated With a Neurological Condition
  ClinicalTrials.gov Identifier: NCT00224016 - Active, not recruiting
  Detrusor Hyperreflexia
  
• FESOTERODINE FLEXIBLE DOSE STUDY
  ClinicalTrials.gov Identifier: NCT00536484 - Recruiting
  Overactive Bladder
  
• A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
  ClinicalTrials.gov Identifier: NCT00333112 - Active, not recruiting
  Urinary Incontinence
  
• NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder
  ClinicalTrials.gov Identifier: NCT00213577 - Terminated
  Overactive Bladder
  
• Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
  ClinicalTrials.gov Identifier: NCT00313924 - Recruiting
  Overactive Bladder
  
• A Two-Part Study to Determine: Best Medication Formulation and Food Effect
  ClinicalTrials.gov Identifier: NCT00427596 - Recruiting
  Overactive Bladder
  
• Surface Nerve Stimulation Treatment for OAB in Children
  ClinicalTrials.gov Identifier: NCT00282490 - Recruiting
  Overactive Bladder; Urinary Incontinence
  
• Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
  ClinicalTrials.gov Identifier: NCT00335660 - Recruiting
  Overactive Bladder Syndrome
  
• This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
  ClinicalTrials.gov Identifier: NCT00479596 - Recruiting
  Overactive Bladder
  
• Study of VESIcare® In OAB Subjects to Evaluate Symptom Bother and Health Related Quality of Life
  ClinicalTrials.gov Identifier: NCT00573508 - Recruiting
  Urinary Bladder, Overactive
  
• Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003725 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage I bladder cancer; stage 0 bladder cancer; recurrent bladder cancer
  
• Enhancing Conservative Treatment for Urge Incontinence
  ClinicalTrials.gov Identifier: NCT00223821 - Recruiting
  Urinary Incontinence; Overactive Bladder
  
• SMP-986 Phase 2 Proof of Concept in Patients With OABS
  ClinicalTrials.gov Identifier: NCT00409539 - Recruiting
  Overactive Bladder Syndrome (OABS)
  
• InSite for Urinary Urgency-Frequency
  ClinicalTrials.gov Identifier: NCT00549094 - Recruiting
  Urinary Bladder, Overactive
  
• High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003623 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage I bladder cancer; stage 0 bladder cancer; prevention of bladder cancer
  
• Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00052637 - Active, not recruiting
  Bladder Cancer; recurrent bladder cancer; stage 0 bladder cancer
  
• Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00042887 - Active, not recruiting
  stage 0 bladder cancer; stage I bladder cancer; recurrent bladder cancer; transitional cell carcinoma of the bladder
  
• Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00095589 - Recruiting
  Bladder Cancer; stage 0 bladder cancer; stage I bladder cancer; transitional cell carcinoma of the bladder
  
• Combination Chemotherapy in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00005047 - Active, not recruiting
  stage I bladder cancer; stage II bladder cancer; transitional cell carcinoma of the bladder
  
• Surgery and BCG in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00002990 - Active, not recruiting
  stage 0 bladder cancer; stage I bladder cancer; transitional cell carcinoma of the bladder
  
• Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00089128 - Active, not recruiting
  transitional cell carcinoma of the bladder; recurrent bladder cancer; stage III bladder cancer; stage IV bladder cancer
  
• Prospective Trial to Evaluate Efficacy and Accuracy of a Portable Ultrasound Scanner for Non-Invasive Bladder Volume Measurement (BladderScan BVI3000) in Patients After Radical Cystectomy and Bladder Reconstruction
  ClinicalTrials.gov Identifier: NCT00512174 - Recruiting
  Bladder Substitution; Reconstructed Bladder
  
• Safety and Efficacy of Solifenacin in Men With OAB and Detrusor Underactivity
  ClinicalTrials.gov Identifier: NCT00441428 - Recruiting
  Overactive Bladder; Detrusor Underactivity
  
• BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00023842 - Active, not recruiting
  stage 0 bladder cancer; recurrent bladder cancer; transitional cell carcinoma of the bladder
  
• Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003129 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage I bladder cancer; stage 0 bladder cancer
  
• Combination Chemotherapy in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00014534 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder
  
• Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003824 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage 0 bladder cancer; recurrent bladder cancer
  
• Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
  ClinicalTrials.gov Identifier: NCT00462488 - Recruiting
  Urinary Bladder Cancer; Bladder Cancer; Bladder Neoplasms; Bladder Tumors
  
• Biological Therapy in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003779 - Active, not recruiting
  stage I bladder cancer; stage 0 bladder cancer
  
• Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
  ClinicalTrials.gov Identifier: NCT00234039 - Recruiting
  Recurrent Bladder Cancer; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Transitional Cell Carcinoma of the Bladder
  
• Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006118 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder
  
• Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003642 - Active, not recruiting
  stage III bladder cancer; stage II bladder cancer; transitional cell carcinoma of the bladder
  
• Combination Chemotherapy in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003701 - Active, not recruiting
  stage III bladder cancer; childhood kidney/urinary cancer; transitional cell carcinoma of the bladder; ...
  
• Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00088946 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage 0 bladder cancer; stage I bladder cancer
  
• Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00005086 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage IV bladder cancer
  
• Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00002919 - Active, not recruiting
  stage II bladder cancer; transitional cell carcinoma of the bladder
  
• Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006105 - Active, not recruiting
  stage II bladder cancer; stage III bladder cancer; stage IV bladder cancer; Drug Toxicity
  
• Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003640 - Active, not recruiting
  stage III bladder cancer; stage II bladder cancer; childhood kidney/urinary cancer; transitional cell carcinoma of the bladder
  
• Evaluation Study of Ultrasound Bladder Scanner for Monitoring Bladder Function
  ClinicalTrials.gov Identifier: NCT00277615 - Recruiting
  Dysfunction of the Urinary Bladder
  
• Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00002490 - Active, not recruiting
  stage I bladder cancer; transitional cell carcinoma of the bladder
  
• Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00033436 - Active, not recruiting
  stage I bladder cancer; stage II bladder cancer; stage III bladder cancer; transitional cell carcinoma of the bladder
  
• Cost-Effectiveness in Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00126958 - Active, not recruiting
  Bladder Cancer
  
• Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00002914 - Active, not recruiting
  recurrent urethral cancer; transitional cell carcinoma of the bladder; recurrent bladder cancer; ...
  
• Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00054626 - Recruiting
  stage II bladder cancer; stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder